Vigil

BIOLOGICAL8 trials

Conditions

Advanced Gynecological CancersBreast CancerCervical CancerEndometrial CancerEwing Family of TumorsEwing SarcomaEwing's SarcomaEwing's Sarcoma Metastatic

Phase 1

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

CompletedNCT02574533

Gradalis, Inc.Malignant Melanoma, Melanoma, Melanoma Recurrent

Start: 2015-10-31End: 2017-09-30Updated: 2017-09-27

Phase 2

A Trial of Vigil for Participants With Ovarian Cancer

Active, not recruitingNCT02346747

Gradalis, Inc.Ovarian Cancer, Ovarian Neoplasms

Start: 2015-02-28End: 2028-12-31Updated: 2025-10-29

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

CompletedNCT02511132

Gradalis, Inc.Ewing's Sarcoma

Start: 2016-02-10End: 2020-12-23Updated: 2022-12-22

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

CompletedNCT02725489

Mary Crowley Medical Research CenterBreast Cancer, Cervical Cancer, Endometrial Cancer +4

Start: 2016-06-03End: 2020-12-02Updated: 2021-01-27

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

CompletedNCT03073525

Gradalis, Inc.Advanced Gynecological Cancers, Cervical Cancer, Ovarian Cancer +1

Start: 2017-05-31End: 2022-05-18Updated: 2023-04-05

Phase 3

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

CompletedNCT01638403

BioprojetTreatment of Excessive Daytime Sleepiness in Narcolepsy

Start: 2010-11-30End: 2012-07-31Updated: 2017-01-31

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

TerminatedNCT03495921

Gradalis, Inc.Ewing Family of Tumors, Ewing Sarcoma, Ewing's Sarcoma Metastatic +10

Start: 2018-08-21End: 2022-01-20Updated: 2023-04-26

Unknown Phase

Expanded Access of Vigil in Solid Tumors

NCT03842865

Gradalis, Inc.Advanced Gynecological Cancers, Cervical Cancer, Ewing Sarcoma +5

Updated: 2025-06-05

2024-11-141 citations

New advances in cancer therapy targeting TGF-β signaling pathways

Molecular Therapy — Oncolytics2023-12-0127 citations

566 ENTPD1 as predictive marker of treatment response to gemogenovatucel-T (Vigil) in newly diagnosed ovarian cancer

Regular and Young Investigator Award Abstracts2022-11-01

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Communications Medicine2022-08-2913 citations

Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials

BMC Psychiatry2022-02-229 citations

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

Clinical Medicine Insights Oncology2022-01-0118 citations

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.

2021-10-2315 citations

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

Journal of Clinical Oncology2021-05-205 citations

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.

2020-12-0186 citations

A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients.

Journal of Clinical Oncology2020-05-2010 citations

Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in <i>BRCA1/2</i>-wt patients.

Journal of Clinical Oncology2020-05-205 citations

Clinical trial in progress: A phase 3 study of maintenance bi-shRNA-furin/GM-CSF-expressing autologous tumor cell vaccine in women with stage IIIb-IV high-grade epithelial ovarian cancer.

Journal of Clinical Oncology2017-05-204 citations

A bi-shRNA<sup>furin</sup> and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors.

Journal of Clinical Oncology2017-05-201 citations